Pulse Biosciences (PLSE) Furnishes Q2 2025 Results; Exhibit 99.1 Attached

Pulse Biosciences, Inc. furnished a Form 8-K to report that it announced financial and operational results for the fiscal quarter ended June 30, 2025.

Rhea-AI Filing Summary

Pulse Biosciences, Inc. furnished a Form 8-K to report that it announced financial and operational results for the fiscal quarter ended June 30, 2025. The company stated that a press release containing those results is attached as Exhibit 99.1 and is incorporated by reference. The filing clarifies that the information and the exhibit are being furnished and are not to be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. No numerical financial metrics or narrative detail from the press release are included in this Form 8-K.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via Form 8-K with no financial figures included; neutral immediate impact.

The filing notifies investors that Pulse Biosciences announced quarterly financial and operational results for the period ended June 30, 2025, and that the full details are provided in an attached press release (Exhibit 99.1). Because the Form 8-K furnishes the release rather than filing it, and because no revenue, profit, cash, or guidance figures are presented in the text, there is insufficient information here to assess performance or revise valuation models. Investors must consult Exhibit 99.1 for substantive metrics.

Corporate Governance Expert

TL;DR: Proper procedural disclosure: the company furnished a press release and explicitly stated the limited legal incorporation of that material.

The 8-K follows standard disclosure practice by furnishing an earnings/operational press release and stating it is not "filed" for Section 18 purposes. This preserves the company's limited liability regarding forward-looking statements and incorporation by reference. The filing is procedural and does not itself change governance, capital structure, or control matters; it simply points stakeholders to the substantive exhibit.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pulse Biosciences (PLSE) report in this Form 8-K?

The company announced that it furnished a press release reporting financial and operational results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in this 8-K considered "filed" with the SEC?

No. The filing states the press release and information are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except by specific reference.

Where can I find the detailed financial metrics referenced in this filing?

The detailed metrics are in the press release attached as Exhibit 99.1; this Form 8-K does not include numerical financial data.

What is the date of the announcement referenced in this 8-K?

The report states the date of the earliest event reported is August 12, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 04:10 PM EDT Learn about SEC filing dates

false 0001625101 0001625101 2025-08-12 2025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 12, 2025

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release issued by Pulse Biosciences, Inc. dated August 12, 2025 - Business Update and Financial Results
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.
Date: August 12, 2025	By:	/s/ Jon Skinner
		Jon Skinner
		Chief Financial Officer (Principal Financial Officer)